MoonLake Immunotherapeutics (MLTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, MoonLake Immunotherapeutics reported revenue of $0. Net income was -$227.3M, or -$3.53 per diluted share. Operating activities generated -$196.0M of cash, leaving -$196.0M of free cash flow. At fiscal year end, MoonLake Immunotherapeutics held $424.4M in total assets against $120.0M in total liabilities, including $334.5M of cash and equivalents.
Open the full interactive MoonLake Immunotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
MoonLake Immunotherapeutics Key Stats
| Share Price | $10.41 |
|---|---|
| Market Cap | $769.5M |
| 52-Week Range | $9.12 – $22.16 |
| Shares Outstanding | 73.9 million (basic, 2026 Q2) |
MoonLake Immunotherapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$4.6M | -$65.1M | -$54.1M | -$143.1M | -$244.8M |
| Pre-Tax Income | -$4.5M | -$64.5M | -$44.0M | -$121.0M | -$229.7M |
| Income Tax | — | $36,366 | $94,388 | $282,199 | $611,000 |
| Net Income | -$4.5M | -$50.0M | -$36.0M | -$118.9M | -$227.3M |
| Diluted EPS | -$0.01 | -$1.70 | -$0.73 | -$1.89 | -$3.53 |
MoonLake Immunotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$69.7M | -$62.4M | -$69.7M | -$61.8M |
| Diluted EPS | -$1.10 | -$0.97 | -$0.98 | -$0.84 |
MoonLake Immunotherapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $666,790 | $39.5M | $451.2M | $180.4M | $334.5M |
| Current Assets | $793,706 | $76.5M | $514.2M | $474.3M | $421.7M |
| Total Assets | $115.8M | $76.8M | $526.5M | $477.9M | $424.4M |
| Current Liabilities | $3.9M | $7.7M | $10.0M | $22.5M | $45.5M |
| Total Long-Term Debt | — | — | — | — | $74.1M |
| Total Liabilities | $7.9M | $8.1M | $13.0M | $24.5M | $120.0M |
| Shareholders' Equity | -$7.1M | $48.9M | $495.7M | $446.8M | $304.5M |
MoonLake Immunotherapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$611,071 | -$55.9M | -$42.8M | -$116.6M | -$196.0M |
| Cash From Investing | — | -$32.3M | -$25.2M | -$205.6M | $203.0M |
| Cash From Financing | -$58,063 | $119.7M | $479.7M | $51.3M | $146.0M |
| Free Cash Flow | — | -$55.9M | -$43.1M | -$117.1M | -$196.0M |
Figures from MoonLake Immunotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full MoonLake Immunotherapeutics financials page for every line item.
MoonLake Immunotherapeutics Company Profile
| Ticker | MLTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Zug, Switzerland |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001821586 |
Frequently Asked Questions
What was MoonLake Immunotherapeutics' revenue in fiscal 2025?
MoonLake Immunotherapeutics (MLTX) reported revenue of $0 for fiscal 2025.
What is MoonLake Immunotherapeutics' annual revenue history?
MoonLake Immunotherapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was MoonLake Immunotherapeutics' net income in fiscal 2025?
MoonLake Immunotherapeutics reported net income of -$227.3M for fiscal 2025.
What was MoonLake Immunotherapeutics' earnings per share (EPS) in fiscal 2025?
MoonLake Immunotherapeutics' diluted EPS was -$3.53 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did MoonLake Immunotherapeutics generate in fiscal 2025?
MoonLake Immunotherapeutics generated -$196.0M of free cash flow in fiscal 2025.
What was MoonLake Immunotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), MoonLake Immunotherapeutics reported revenue of $0.
How much debt does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics reported $74.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of MoonLake Immunotherapeutics are outstanding?
MoonLake Immunotherapeutics reported a weighted average of 73.9 million basic shares outstanding in 2026 Q2.
What is MoonLake Immunotherapeutics' market cap?
Based on its latest closing price, MoonLake Immunotherapeutics (MLTX) has a market capitalization of about $769.5M.
When does MoonLake Immunotherapeutics' fiscal year end?
MoonLake Immunotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is MoonLake Immunotherapeutics headquartered?
MoonLake Immunotherapeutics lists its business address in Zug, Switzerland in its SEC filings.